Issels Integrative Immuno-Oncology January 4, 2018  

Low Survival Cancers May Benefit from Targeting a Tumor Protein

Dear Friend,

Immunotherapy continues to be a major focus in cancer treatment research. Scientists in the United Kingdom recently began early-phase clinical trials of an experimental drug that targets a protein found in many solid tumors.

Using the Immune System to Attack Cancer Cells

Cancer Research UK and Biotecnol Limited are collaborating on development of a first-in-class drug (Fdrug) known as Tb535H. Arising from Trisoma®, Biotecnol's antibody development platform, the drug targets the 5T4/WAIF1 antigen that is believed to contribute to the spread of cancer cells.

As with most immunotherapy treatments, Tb535H works by harnessing the immune system's T cells and directing them to attack and kill cancer cells. Biotecnol has been instrumental in partnering with top cancer institutions to develop promising immune-oncology therapies.

Targeted Cancer Treatment

The discovery of the WAIF1 antigen also occurred as a result of studies at Cancer Research UK's Manchester Institute. While it may ultimately be a target for a number of cancer types, current testing will be limited to cancers with low survival rates, including mesothelioma and small-cell lung carcinoma.

Dr. Nigel Blackburn, director of drug development for Cancer Research UK, acknowledged that the partnership with Biotecnol will accelerate the path of bringing Tb535H to cancer patients. Blackburn also stressed the need for more effective treatment for lung cancer, the cause of 20 percent of cancer deaths in the UK.

Issels® Offers State-of-the-Art Immunotherapy Programs

While immunotherapy is a hot buzzword in cancer treatment today, we have been using non-toxic integrative programs for decades. Contact us to read and hear testimonials from patients with all forms of cancer who have received successful treatment at Issels®.

Low Survival Cancers May Benefit from Targeting a Tumor Protein

Read more interesting articles on the "Issels Cancer Immunotherapy" news/blog posted every Tuesday and Thursday. Check It Out Now »

What Are Tumor Markers?

Tumor markers are substances that are produced by the actual cancer itself or other healthy cells in the body when cancer is present. While the most commonly recognized markers are proteins found in the stool, urine, blood, or other tissue sample from the person, changes to DNA and altered gene expression are starting to be used as tumor markers. Currently, there are over 20 unique tumor markers identified and used for the detection, research and treatment of cancer.

Get the Full Story!

Synthetic Biomarkers May Aid in Early Detection of Ovarian Cancer

Synthetic biomarkers are nanoparticles that interact with tumor proteins. The process releases fragments that can be detected in a patient's urine, resulting in a more accurate test than one conducted on natural biomarkers in the bloodstream.

Get the Full Story!

Videos – What Do Patients Say About Their Experience?

Watch videos of patients who share their own experiences at the Issels clinics with you. Listen to their stories and cancer journeys.

Get the Full Story!

Learn More

Testimonials »

Treatments »

Vaccines »

Statistics »

History »

Locations »

Contact Us »

Connect With Us:

Google +

Contact Info:

Phone: 888-447-7357


Treatments | Testimonials | Contact Us